Cargando…

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?

BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a distinct clinicopathological entity and EBV-associated disease that is highly aggressive. Many patients had failed to respond to conventional chemotherapy or relapsed after treatment. Multi-drug resistance is a major cause that leads...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xudong, Fu, Xiaorui, Dong, Meng, Yang, Zhenzhen, Wu, Shaoxuan, Ma, Mijing, Li, Zhaoming, Wang, Xinhua, Li, Ling, Li, Xin, Sun, Zhenchang, Chang, Yu, Nan, Feifei, Yan, Jiaqin, Mao, Yun, Zhang, Mingzhi, Chen, Qingjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167813/
https://www.ncbi.nlm.nih.gov/pubmed/30302057
http://dx.doi.org/10.1186/s12935-018-0644-6
_version_ 1783360264041660416
author Zhang, Xudong
Fu, Xiaorui
Dong, Meng
Yang, Zhenzhen
Wu, Shaoxuan
Ma, Mijing
Li, Zhaoming
Wang, Xinhua
Li, Ling
Li, Xin
Sun, Zhenchang
Chang, Yu
Nan, Feifei
Yan, Jiaqin
Mao, Yun
Zhang, Mingzhi
Chen, Qingjiang
author_facet Zhang, Xudong
Fu, Xiaorui
Dong, Meng
Yang, Zhenzhen
Wu, Shaoxuan
Ma, Mijing
Li, Zhaoming
Wang, Xinhua
Li, Ling
Li, Xin
Sun, Zhenchang
Chang, Yu
Nan, Feifei
Yan, Jiaqin
Mao, Yun
Zhang, Mingzhi
Chen, Qingjiang
author_sort Zhang, Xudong
collection PubMed
description BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a distinct clinicopathological entity and EBV-associated disease that is highly aggressive. Many patients had failed to respond to conventional chemotherapy or relapsed after treatment. Multi-drug resistance is a major cause that leads to these desperate failures. However, the specific mechanism of drug resistance is still unclear. METHODS: In the previous study, we firstly developed a doxorubicin-resistant ENKL cell line known as SNK-6/ADM, and then a small quantity of side population (SP) cells were derived from SNK-6/ADM and named SNK-6/ADM-SP. In order to explore the biological characteristics and mechanism of drug-resistance of these cells, SNK-6, SNK-6/ADM and SNK-6/ADM-SP cells were utilized to evaluate potentially differences of chemotherapy resistance index (RI), morphology, proliferation, cell cycles, expression of ATP-binding cassette (ABC) transporters (ABCG1, ABCG2 and ABCC4) and surface markers, cytokine sensitivity, and situation of EBV infection. RESULTS: We identified SNK-6/ADM-SP is a specific multidrug resistant cell population with a higher level of RI than SNK-6/ADM. Relevant evaluations showed that SNK-6/ADM-SP presented a series of conserved biological behaviors including relatively poor proliferation ability, high expression of ABCG2, weak sensitivity to IL-15 which could stimulate normal ENKL cells’ proliferation and differentiation, and EBV inhibition with low level of EBV-DNA replication and EBV-antigen expression. CONCLUSIONS: This discovered cellular heterogeneity of ENKL could provide a new perspective to better understand the mechanisms of drug resistance and overcome elusive response to chemotherapy of ENKL.
format Online
Article
Text
id pubmed-6167813
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61678132018-10-09 Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? Zhang, Xudong Fu, Xiaorui Dong, Meng Yang, Zhenzhen Wu, Shaoxuan Ma, Mijing Li, Zhaoming Wang, Xinhua Li, Ling Li, Xin Sun, Zhenchang Chang, Yu Nan, Feifei Yan, Jiaqin Mao, Yun Zhang, Mingzhi Chen, Qingjiang Cancer Cell Int Primary Research BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a distinct clinicopathological entity and EBV-associated disease that is highly aggressive. Many patients had failed to respond to conventional chemotherapy or relapsed after treatment. Multi-drug resistance is a major cause that leads to these desperate failures. However, the specific mechanism of drug resistance is still unclear. METHODS: In the previous study, we firstly developed a doxorubicin-resistant ENKL cell line known as SNK-6/ADM, and then a small quantity of side population (SP) cells were derived from SNK-6/ADM and named SNK-6/ADM-SP. In order to explore the biological characteristics and mechanism of drug-resistance of these cells, SNK-6, SNK-6/ADM and SNK-6/ADM-SP cells were utilized to evaluate potentially differences of chemotherapy resistance index (RI), morphology, proliferation, cell cycles, expression of ATP-binding cassette (ABC) transporters (ABCG1, ABCG2 and ABCC4) and surface markers, cytokine sensitivity, and situation of EBV infection. RESULTS: We identified SNK-6/ADM-SP is a specific multidrug resistant cell population with a higher level of RI than SNK-6/ADM. Relevant evaluations showed that SNK-6/ADM-SP presented a series of conserved biological behaviors including relatively poor proliferation ability, high expression of ABCG2, weak sensitivity to IL-15 which could stimulate normal ENKL cells’ proliferation and differentiation, and EBV inhibition with low level of EBV-DNA replication and EBV-antigen expression. CONCLUSIONS: This discovered cellular heterogeneity of ENKL could provide a new perspective to better understand the mechanisms of drug resistance and overcome elusive response to chemotherapy of ENKL. BioMed Central 2018-10-01 /pmc/articles/PMC6167813/ /pubmed/30302057 http://dx.doi.org/10.1186/s12935-018-0644-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Zhang, Xudong
Fu, Xiaorui
Dong, Meng
Yang, Zhenzhen
Wu, Shaoxuan
Ma, Mijing
Li, Zhaoming
Wang, Xinhua
Li, Ling
Li, Xin
Sun, Zhenchang
Chang, Yu
Nan, Feifei
Yan, Jiaqin
Mao, Yun
Zhang, Mingzhi
Chen, Qingjiang
Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
title Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
title_full Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
title_fullStr Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
title_full_unstemmed Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
title_short Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
title_sort conserved cell populations in doxorubicin-resistant human nasal natural killer/t cell lymphoma cell line: super multidrug resistant cells?
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167813/
https://www.ncbi.nlm.nih.gov/pubmed/30302057
http://dx.doi.org/10.1186/s12935-018-0644-6
work_keys_str_mv AT zhangxudong conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT fuxiaorui conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT dongmeng conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT yangzhenzhen conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT wushaoxuan conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT mamijing conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT lizhaoming conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT wangxinhua conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT liling conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT lixin conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT sunzhenchang conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT changyu conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT nanfeifei conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT yanjiaqin conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT maoyun conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT zhangmingzhi conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells
AT chenqingjiang conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells